Diligent Announces Diligent AI to Empower Governance, Risk and Compliance Professionals to Better Manage and Respond to Risk
11.6.2024 15:00:00 EEST | Business Wire | Press release
Diligent, a leading GRC SaaS company, today announced Diligent AI, a powerful set of artificial intelligence capabilities within the Diligent One Platform that enhance how organizations understand, anticipate and mitigate risks. Diligent AI will enable users to identify risks, safeguard data and democratize the decision-making processes, driving resilience and empowering organizations with certainty and clarity like never before.
"Company leaders face a dynamic and evolving risk environment. It’s imperative to turn data into strategic intelligence to anticipate and prevent risks, rather than just respond to them,” said Brian Stafford, President and CEO of Diligent. “Diligent’s AI-enhanced platform is uniquely positioned to connect all aspects of governance, risk and compliance, delivering customized insights to elevate governance and clarify risk.”
Diligent AI helps leaders amplify critical insights while working together across the organization, using risk as a shared language. Leaders can expand resources and achieve greater results through integrated automation, enhance stakeholder communication by tailoring information to board members, chief financial officers, chief risk officers and other executives, and enhance decision making by breaking down information silos across governance, risk and compliance (GRC) functions.
Register for the first session in Diligent’s AI webinar series starting on June 13, where Diligent leaders and experts will discuss Diligent AI capabilities and how they:
Elevate Governance for Boards and Leaders:
- Creating efficient, context-aware summaries of board materials to help directors easily digest information and glean insights.
- Providing AI-powered insights into a company’s ESG focus and self-disclosed risk factors, enabling peer comparison and helping to identify industry trends.
- Quickly assisting with boards-related questions through a 24/7 AI-powered virtual assistant.
Clarify Risk for Audit, Risk and Compliance Teams:
- Simplifying the tedious process of mapping internal controls to regulatory requirements, enabling GRC professionals to efficiently demonstrate compliance.
- Identifying changes between two versions of the same regulation, categorizing them as significant, moderate or minor, enabling users to efficiently update related policies, risks and controls.
- Empowering users to create, edit and troubleshoot data integrations and data analytics scripts using plain language. This brings Diligent's powerful robotics capabilities (also known as ACL Analytics) to a broader audience.
Additional capabilities will be added to Diligent AI over the coming months that empower GRC professionals to better mitigate risks and stay on top of changing regulatory requirements, and help corporate directors govern more effectively amidst escalating risks and information overload.
“Diligent AI adds to the breadth of the Diligent One Platform by enabling leaders to more quickly and effectively respond to risk in a competitive environment,” said Phil Lim, Global AI Champion at Diligent. “Our thoughtful and ethical approach to AI use, guided by industry-leading principles, means customers can feel secure in knowing that AI interacts with their data safely and securely, and only with their prior consent.”
The use of Generative AI in GRC must uphold the highest standards of safety and security, and Diligent has committed to the safe, secure and ethical use of AI through its guiding principles. This ensures users’ data stays their own, generated content is clearly labelled and users must always opt-in before using AI with their data. Learn more about Diligent’s AI Principles here.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611912292/en/
Contacts
Media
Julia Stoyanov
Communications Director, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 15:40:00 EEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 15:30:00 EEST | Press release
ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes. The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every aspect of well delivery through a technology-enabled operating model. It combines digital drilling workflows with au
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom